Last reviewed · How we verify
LY3866288
At a glance
| Generic name | LY3866288 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (PHASE1)
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (PHASE3)
- A Study of LY3866288 in Healthy Participants (PHASE1)
- A Study of [14C]-LY3866288 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3866288 CI brief — competitive landscape report
- LY3866288 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI